Wikisage, the free encyclopedia of the second generation, is digital heritage

Eslicarbazepine: Difference between revisions

From Wikisage
Jump to navigation Jump to search
(fix)
Line 31: Line 31:
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5
|colspan=2| <center>
|colspan=2| <center>
: [[wikipedia:eslicarbazepine|eslicarbazapine]]
: [[wikipedia:eslicarbazepine|eslicarbazepine]]
<ref>http://www.whocc.no/atc_ddd_index/?code=N03AF04</ref></center>
<ref>http://www.whocc.no/atc_ddd_index/?code=N03AF04</ref></center>
|}
|}

Revision as of 03:22, 24 September 2015

S-licarbazepine is an AED. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic epilepsy of infancy[1][2]

Pharmacy and chemistry

Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the EMA (Zerebix TM) and recently by the American FDA[3] Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)[4]

Pharmacology

Mild inducers

After de Leon the following AED groups as mild inducers:

  • clobazam
  • eslicarbazepine
  • rufinamide
  • felbamate
  • lamotrigine
  • oxcarbazepine
  • topiramate
  • vigabatrin
  • VPA

[5]

Cutaneous adverse effects

Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine

ATC code N03

eslicarbazepine
[6]

Bioquivalence

Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects

References